
1. Neurol Neuroimmunol Neuroinflamm. 2020 Dec 15;8(1). pii: e930. doi:
10.1212/NXI.0000000000000930. Print 2021 Jan.

Treating MS after surviving PML: Discrete strategies for rescue, remission, and
recovery patient 2: From the National Multiple Sclerosis Society Case Conference 
Proceedings.

Cruz RA(1), Hogan N(1), Sconzert J(1), Sconzert M(1), Major EO(1), Lisak RP(1),
Melamed E(1), Varkey TC(1), Meltzer E(1), Goodman A(1), Komogortsev O(1), Parsons
MS(1), Costello K(1), Graves JS(1), Newsome S(1), Zamvil SS(1), Frohman EM(2),
Frohman TC(2).

Author information: 
(1)From the Department of Neurology (R.A.C., E. Melamed, T.C.V., E. Meltzer),
Dell Medical School, University of Texas at Austin; Department of Ophthalmology
(N.H.), University of Texas Southwestern, Dallas; Wellness Care Centers and
Pediatric Rehabilitation (J.S.), Denton, TX; Ascension Seton Medical Center
(M.S.), Austin, TX; National Institutes of Health (E.O.M.), Bethesda, MD;
Departments of Neurology, and Biochemistry, Microbiology and Immunology (R.P.L.),
Wayne State University, Detroit, MI; Colangelo College of Business (T.C.V.),
Grand Canyon University, Phoenix, AZ; Department of Neurology (A.G.), University 
of Rochester, NY; Department of Computer Science (O.K.), Texas State University, 
San Marcos; Division of Microbiology and Immunology (M.S.P.), Yerkes National
Primate Research Center, and Department of Pathology and Laboratory Medicine
(M.S.P.), Emory University, Atlanta, GA; The National Multiple Sclerosis Society 
(K.C.), New York, NY; Department of Neurology (J.S.G.), University of California 
at San Diego; Department of Neurology (S.N.), Johns Hopkins Hospital, Bethesda,
MD; Department of Neurology and Program in Immunology (S.S.Z.), University of
California, San Francisco; andDepartments of Neurology, Ophthalmology &
Neurosurgery (E.M.F., T.C.F.), Dell Medical School at the University of Texas at 
Austin.
(2)From the Department of Neurology (R.A.C., E. Melamed, T.C.V., E. Meltzer),
Dell Medical School, University of Texas at Austin; Department of Ophthalmology
(N.H.), University of Texas Southwestern, Dallas; Wellness Care Centers and
Pediatric Rehabilitation (J.S.), Denton, TX; Ascension Seton Medical Center
(M.S.), Austin, TX; National Institutes of Health (E.O.M.), Bethesda, MD;
Departments of Neurology, and Biochemistry, Microbiology and Immunology (R.P.L.),
Wayne State University, Detroit, MI; Colangelo College of Business (T.C.V.),
Grand Canyon University, Phoenix, AZ; Department of Neurology (A.G.), University 
of Rochester, NY; Department of Computer Science (O.K.), Texas State University, 
San Marcos; Division of Microbiology and Immunology (M.S.P.), Yerkes National
Primate Research Center, and Department of Pathology and Laboratory Medicine
(M.S.P.), Emory University, Atlanta, GA; The National Multiple Sclerosis Society 
(K.C.), New York, NY; Department of Neurology (J.S.G.), University of California 
at San Diego; Department of Neurology (S.N.), Johns Hopkins Hospital, Bethesda,
MD; Department of Neurology and Program in Immunology (S.S.Z.), University of
California, San Francisco; andDepartments of Neurology, Ophthalmology &
Neurosurgery (E.M.F., T.C.F.), Dell Medical School at the University of Texas at 
Austin. Elliot.frohman@austin.utexas.edu.

Erratum in
    Neurol Neuroimmunol Neuroinflamm. 2021 Feb 1;8(2):.

DOI: 10.1212/NXI.0000000000000930 
PMCID: PMC7803334
PMID: 33434885 

